Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice

FEMS Immunology and Medical Microbiology

Volumn 47, Issue 1, 2006, Pages 107-115

  Ohama, Minoru ^a   Hiramatsu, Kazufumi ^a   Miyajima, Yoshiko ^a   Kishi, Kenji ^a   Nasu, Masaru ^a   Kadota, Jun Ichi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Mucosal immunization; Pili protein; Pneumonia; Pseudomonas aeruginosa; Pulmonary infection

Indexed keywords

BACTERIAL PROTEIN; BOVINE SERUM ALBUMIN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 4;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIUM PILUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IMMUNIZATION; LUNG INFECTION; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, BACTERIAL; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; FIMBRIAE PROTEINS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; LUNG; MICE; MICE, INBRED BALB C; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TH1 CELLS; TRACHEA;

EID: 33646749084     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2006.00069.x     Document Type: Article

References (37)

1. Abbas AK, Murphy KM Sher A 1996 Functional diversity of helper T lymphocytes. Nature 383 : 787 793.
2. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S Metzger DW 2001 Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69 : 6718 6724.
3. Bennett-Guerrero E, McIntosh TJ, Barclay GR, Snyder DS, Gibbs RJ, Mythen MG Poxton IR 2000 Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. Infect Immun 68 : 6202 6208.
4. Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E McGhee JR 1999 IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 162 : 122 128.
5. Bradley DE 1980 A function of Pseudomonas aeruginosa PAO polar pili : twitching motility. Can J Microbiol 26 : 146 154.
6. Brewer CS, Wunderink RG, Jones CB Leeper KV Jr. 1996 Ventilator- associated pneumonia due to Pseudomonas aeruginosa. Chest 109 : 1019 1029.
7. Castric PA Deal CD 1994 Differentiation of Pseudomonas aeruginosa pili based on sequence and B-cell epitope analyses. Infect Immun 62 : 371 376.
8. Cripps AW, Dunkley ML Clancy RL 1994 Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infection in rats. Infect Immun 62 : 1427 1436.
9. Cryz SJ Jr., Furer E Que JU 1991 Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine. Infect Immun 59 : 45 50.
10. DiMango E, Zar HJ, Bryan R Prince A 1995 Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8. J Clin Invest 96 : 2204 2210.
11. Doig P, Sastry PA, Hodges RS, Lee KK, Paranchych W Irvin RT 1990 Inhibition of pilus-mediated adhesion of Pseudomonas aeruginosa to human buccal epithelial cells by monoclonal antibodies directed against pili. Infect Immun 58 : 124 130.
12. Frost LS Paranchych W 1977 Composition and molecular weight of pili purified from Pseudomonas aeruginosa K. J Bacteriol 131 : 259 269.
13. Gales AC, Jones RN, Turnidge J, Rennie R Ramphal R 2001 Characterization of Pseudomonas aeruginosa isolates : occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 32 suppl 2 : S146 S155.
14. Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, Kolsch E, Podlaski FJ, Gately MK Rude E 1995 Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 25 : 823 829.
15. Greenberger MJ, Kunkel SL, Strieter RM, Lukacs NW, Bramson J, Gauldie J, Graham FL, Hitt M, Danforth JM Standiford TJ 1996 IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 157 : 3006 3012.
16. Hahn HP 1997 The type-4 pilus is the major virulence-associated adhesin of Pseudomonas aeruginosa- a review. Gene 192 : 99 108.
17. Holder IA, Joseph G Naglich MS 1986 Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa : immunization using divalent flagella preparations. J Trauma 26 : 118 122.
18. Irvin RT, Doig P, Lee KK, Sastry PA, Paranchych W, Todd T Hodges RS 1989 Characterization of the Pseudomonas aeruginosa pilus adhesin : confirmation that the pilin structural protein subunit contains a human epithelial cell-binding domain. Infect Immun 57 : 3720 3726.
19. Jang IJ, Kim IS, Park WJ, et al 1999 Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine. Vaccine 17 : 158 168.
20. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Freidland IR Sahm DF 2003 Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 47 : 1681 1688.
21. Lynch JM, Briles DE Metzger DW 2003 Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 71 : 4780 4788.
22. Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH Dunnick WA 1997 Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. Eur J Immunol 27 : 1958 1965.
23. Obritsch MD, Fish DN, MacLaren R Jung R 2004 National surveillance of antimicrobial resistance Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 48 : 4606 4610.
24. O'Toole GA Kolter R 1998 Flagellar and twitching motility are necessary for Pseudomonas aeruginosa biofilm development. Mol Microb 30 : 295 304.
25. Pascale JM, Shaw MM, Durant PJ, Amador AA, Bartlett MS, Smith JW, Gregory RL McLaughlin GL 1999 Intranasal immunization confers protection against murine Pneumocystis carinii lung infection. Infect Immun 67 : 805 809.
26. Priebe GP, Meluleni GJ, Coleman FT, Goldberg JB Pier GB 2003 Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun 71 : 1453 1461.
27. Rello J, Lorente C, Diaz E, Bodi M, Boque C, Sandiumenge A Santamaria JM 2003 Incidence, etiology, and outcome of nosocomial pneumonia in ICU patients requiring percutaneous tracheotomy for mechanical ventilation. Chest 124 : 2239 2243.
28. Rhomberg PR, Jones RN, Sader HS the MYSTIC Programme (US) Study Group. 2004 Results from the Meropenem yearly susceptibility test information collection (MYSTIC) programme : report of the 2001 data from 15 United States medical centers. Int J Antimicrob Agents 23 : 52 59.
29. Richards MJ, Edwards JR, Culver DH Gaynes RP 1999 Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27 : 887 892.
30. Sokol PA, Kooi C, Cachia P Woods DE 2000 Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia. J Infect Dis 181 : 1682 1692.
31. Tang H, Kays M Prince A 1995 Role of Pseudomonas aeruginosa pili in acute pulmonary infection. Infect Immun 63 : 1278 1285.
32. Theilacker C, Coleman FT, Mueschenborn S, Llosa N, Grout M Pier GB 2003 Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine. Infect Immun 71 : 3875 3884.
33. Thomas LD, Dunkley ML, Moore R, Reynolds S, Bastin DA, Kyd JM Cripps AW 2000 Catalase immunization from Pseudomonas aeruginosa enhances bacterial clearance in the rat lung. Vaccine 19 : 348 357.
34. Thomas LD, Kyd JM, Bastin DA, Dunkley ML Cripps AW 2003 Immunisation with non-integral OMPs promotes pulmonary clearance of Pseudomonas aeruginosa. FEMS Immunol Med Microbiol 37 : 155 160.
35. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC Hemmer M 1995 The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274 : 639 644.
36. von Specht BU, Strigl G, Ehret W Brendel W 1987 Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection. Infection 15 : 408 412.
37. Watford WT, Moriguchi M, Morinobu A O'Shea JJ 2003 The biology of IL-12 : coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14 : 361 368.